Yahoo
NYSE American - BOATS Real Time Price USD

AEON Biopharma, Inc. (AEON)

0.2740 -0.0200 (-6.80%)
At close: October 30 at 4:00:00 PM EDT
0.2895 +0.0155 (+5.66%)
Overnight: 8:56:30 PM EST
Chart Range Bar
Loading chart for AEON
Chart does not reflect overnight price.
  • Previous Close 0.2940
  • Open 0.2844
  • Bid 0.2600 x 120000
  • Ask 0.3100 x 190000
  • Day's Range 0.2701 - 0.2900
  • 52 Week Range 0.1770 - 1.4500
  • Volume 774,171
  • Avg. Volume 7,549,048
  • Market Cap (intraday) 16.189M
  • Beta (5Y Monthly) 0.69
  • PE Ratio (TTM) --
  • EPS (TTM) -4.3900
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.82

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

www.aeonbiopharma.com

8

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AEON
75.09%
S&P 500 (^GSPC)
10.73%

1-Year Return

AEON
67.54%
S&P 500 (^GSPC)
11.11%

3-Year Return

AEON
99.92%
S&P 500 (^GSPC)
81.91%

5-Year Return

AEON
99.96%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -1.16M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-1M
-800K
-600K
-400K
-200K
0
0.0%

Analyst Insights

View More

Analyst Price Targets

1.20
1.82 Average
0.2740 Current
2.10 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/1/2026
Analyst Lake Street
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 1 -> 2

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -141.53%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -54.62M

  • Diluted EPS (ttm)

    -4.3900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.43M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: